Impact of Early Corticosteroids on Preventing Clinical Deterioration in Non-critically Ill Patients Hospitalized with COVID-19: A Multi-hospital Cohort Study
Introduction While guidelines stronglyrecommend dexamethasone in critical COVID-19, the optimal threshold to initiate corticosteroids in non-critically ill patients with COVID-19 remains unclear. Using data from a state-wide COVID-19 registry, we evaluated the effectiveness of early corticosteroids for preventing clinical deterioration among non-critically ill patients hospitalized for COVID-19 and receiving non-invasive oxygen therapy. Methods This was a target trial using observational data from patients hospitalized for COVID-19 at 39 hospitals participating in the MI-COVID19 registry between March 16, 2020 and August 24, 2020. We studied the impact of corticosteroids initiated within 2 calendar days of hospitalization (“early steroids”) versus no early steroids among non-ICU patients with laboratory-confirmed SARS-CoV2 receiving non-invasive supplemental oxygen therapy. Our primary outcome was a composite of in-hospital mortality, transfer to intensive care, and receipt of invasive mechanical ventilation. We used inverse probability of treatment weighting (IPTW) and propensity score-weighted regression to measure the association of early steroids and outcomes. Results Among 1002 patients meeting study criteria, 231 (23.1%) received early steroids. After IPTW, to balance potential confounders between the treatment groups, early steroids were not associated with a decrease in the composite outcome (aOR 1.1, 95%CI 0.8–1.6) or in any components of the primary outcome. Conclusion We found no evidence that early corticosteroid therapy prevents clinical deterioration among hospitalized non-critically ill COVID-19 patients receiving non-invasive oxygen therapy. Further studies are needed to determine the optimal threshold for initiating corticosteroids in this population..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Infectious diseases and therapy - 11(2022), 2 vom: 10. März, Seite 887-898 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Swaminathan, Lakshmi [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
COVID-19 therapeutics |
|---|
| Anmerkungen: |
© The Author(s) 2022 |
|---|
| doi: |
10.1007/s40121-022-00615-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR046611940 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR046611940 | ||
| 003 | DE-627 | ||
| 005 | 20230519182134.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220329s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40121-022-00615-x |2 doi | |
| 035 | |a (DE-627)SPR046611940 | ||
| 035 | |a (SPR)s40121-022-00615-x-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Swaminathan, Lakshmi |e verfasserin |0 (orcid)0000-0002-9307-170X |4 aut | |
| 245 | 1 | 0 | |a Impact of Early Corticosteroids on Preventing Clinical Deterioration in Non-critically Ill Patients Hospitalized with COVID-19: A Multi-hospital Cohort Study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2022 | ||
| 520 | |a Introduction While guidelines stronglyrecommend dexamethasone in critical COVID-19, the optimal threshold to initiate corticosteroids in non-critically ill patients with COVID-19 remains unclear. Using data from a state-wide COVID-19 registry, we evaluated the effectiveness of early corticosteroids for preventing clinical deterioration among non-critically ill patients hospitalized for COVID-19 and receiving non-invasive oxygen therapy. Methods This was a target trial using observational data from patients hospitalized for COVID-19 at 39 hospitals participating in the MI-COVID19 registry between March 16, 2020 and August 24, 2020. We studied the impact of corticosteroids initiated within 2 calendar days of hospitalization (“early steroids”) versus no early steroids among non-ICU patients with laboratory-confirmed SARS-CoV2 receiving non-invasive supplemental oxygen therapy. Our primary outcome was a composite of in-hospital mortality, transfer to intensive care, and receipt of invasive mechanical ventilation. We used inverse probability of treatment weighting (IPTW) and propensity score-weighted regression to measure the association of early steroids and outcomes. Results Among 1002 patients meeting study criteria, 231 (23.1%) received early steroids. After IPTW, to balance potential confounders between the treatment groups, early steroids were not associated with a decrease in the composite outcome (aOR 1.1, 95%CI 0.8–1.6) or in any components of the primary outcome. Conclusion We found no evidence that early corticosteroid therapy prevents clinical deterioration among hospitalized non-critically ill COVID-19 patients receiving non-invasive oxygen therapy. Further studies are needed to determine the optimal threshold for initiating corticosteroids in this population. | ||
| 650 | 4 | |a Corticosteroid therapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a COVID-19 therapeutics |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a SARS-COV2 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Viral infections |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Kaatz, Scott |4 aut | |
| 700 | 1 | |a Chubb, Heather |4 aut | |
| 700 | 1 | |a Tae, Kim |4 aut | |
| 700 | 1 | |a Ramesh, Mayur S. |4 aut | |
| 700 | 1 | |a Fadel, Raef |4 aut | |
| 700 | 1 | |a Big, Cecilia |4 aut | |
| 700 | 1 | |a Jones, Jessica |4 aut | |
| 700 | 1 | |a Flanders, Scott A. |4 aut | |
| 700 | 1 | |a Prescott, Hallie C. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Infectious diseases and therapy |d Heidelberg : Springer, 2012 |g 11(2022), 2 vom: 10. März, Seite 887-898 |w (DE-627)SPR032878133 |w (DE-600)2701611-0 |x 2193-6382 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2022 |g number:2 |g day:10 |g month:03 |g pages:887-898 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40121-022-00615-x |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2022 |e 2 |b 10 |c 03 |h 887-898 | ||